These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 14709245)

  • 1. HIV Type 1 replication in cerebrospinal fluid of patients with AIDS-related non-Hodgkin's lymphoma receiving chemotherapy and antiretroviral therapy.
    Giancola ML; Uccella I; Alba L; Lorenzini P; Soldani F; Capobianchi M; Ruco L; Perno CF; Antinori A
    AIDS Res Hum Retroviruses; 2003 Dec; 19(12):1091-5. PubMed ID: 14709245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients.
    Antinori A; Giancola ML; Grisetti S; Soldani F; Alba L; Liuzzi G; Amendola A; Capobianchi M; Tozzi V; Perno CF
    AIDS; 2002 Sep; 16(14):1867-76. PubMed ID: 12351946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic non-Hodgkin lymphoma in HIV-infected patients with effective suppression of HIV replication: persistent occurrence but improved survival.
    Gérard L; Galicier L; Maillard A; Boulanger E; Quint L; Matheron S; Cardon B; Meignin V; Oksenhendler E
    J Acquir Immune Defic Syndr; 2002 Aug; 30(5):478-84. PubMed ID: 12154338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical epidemiology of Hodgkin lymphoma in HIV-infected patients in the highly active antiretroviral therapy (HAART) era.
    Vilchez RA; Finch CJ; Jorgensen JL; Butel JS
    Medicine (Baltimore); 2003 Mar; 82(2):77-81. PubMed ID: 12640183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of concomitant antiblastic chemotherapy and highly active antiretroviral therapy on human immunodeficiency virus (HIV) viremia and genotyping in HIV-infected patients with non-Hodgkin lymphoma.
    Simonelli C; Zanussi S; Cinelli R; Dal Maso L; Di Gennaro G; D'Andrea M; Nasti G; Spina M; Vaccher E; De Paoli P; Tirelli U
    Clin Infect Dis; 2003 Sep; 37(6):820-7. PubMed ID: 12955644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.
    Canestri A; Lescure FX; Jaureguiberry S; Moulignier A; Amiel C; Marcelin AG; Peytavin G; Tubiana R; Pialoux G; Katlama C
    Clin Infect Dis; 2010 Mar; 50(5):773-8. PubMed ID: 20100092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AIDS-related systemic non-Hodgkin's lymphoma at a large community program.
    Vilchez RA; Kozinetz CA; Jorgensen JL; Kroll MH; Butel JS
    AIDS Res Hum Retroviruses; 2002 Mar; 18(4):237-42. PubMed ID: 11860669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration.
    Eggers C; Hertogs K; Stürenburg HJ; van Lunzen J; Stellbrink HJ
    AIDS; 2003 Sep; 17(13):1897-906. PubMed ID: 12960822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy.
    Antinori A; Cingolani A; Alba L; Ammassari A; Serraino D; Ciancio BC; Palmieri F; De Luca A; Larocca LM; Ruco L; Ippolito G; Cauda R
    AIDS; 2001 Aug; 15(12):1483-91. PubMed ID: 11504980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Non Hodgkin's and Hodgkin's lymphomas and HIV: frequency, outcome and immune response under HAART; Clermont-Ferrand University Hospital, 1991-2003].
    Jacomet C; Lesens O; Villemagne B; Darcha C; Tournilhac O; Henquell C; Cormerais L; Gourdon F; Peigue-Lafeuille H; Travade P; Beytout J; Laurichesse H
    Med Mal Infect; 2006 Mar; 36(3):157-62. PubMed ID: 16503104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment.
    Mellgren A; Antinori A; Cinque P; Price RW; Eggers C; Hagberg L; Gisslén M
    Antivir Ther; 2005; 10(6):701-7. PubMed ID: 16218168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy.
    Molina A; Krishnan AY; Nademanee A; Zabner R; Sniecinski I; Zaia J; Forman SJ
    Cancer; 2000 Aug; 89(3):680-9. PubMed ID: 10931469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure.
    Spudich S; Lollo N; Liegler T; Deeks SG; Price RW
    J Infect Dis; 2006 Dec; 194(12):1686-96. PubMed ID: 17109340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlates of independent HIV-1 replication in the CNS and of its control by antiretrovirals.
    De Luca A; Ciancio BC; Larussa D; Murri R; Cingolani A; Rizzo MG; Giancola ML; Ammassari A; Ortona L
    Neurology; 2002 Aug; 59(3):342-7. PubMed ID: 12177366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cerebrospinal fluid viral load in HIV-1 positive hemophilic patients treated with HAART].
    Corti ME; Villafañe MF; Baré P; Alves Rosa F; Cermelj M; Candela M; Pérez Bianco R; Tezanos Pinto M
    Medicina (B Aires); 2001; 61(6):821-4. PubMed ID: 11808421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid viral loads reach less than 2 copies/ml in HIV-1-infected patients with effective antiretroviral therapy.
    Yilmaz A; Svennerholm B; Hagberg L; Gisslén M
    Antivir Ther; 2006; 11(7):833-7. PubMed ID: 17302245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors influencing cerebrospinal fluid and plasma HIV-1 RNA detection rate in patients with and without opportunistic neurological disease during the HAART era.
    Christo PP; Greco DB; Aleixo AW; Livramento JA
    BMC Infect Dis; 2007 Dec; 7():147. PubMed ID: 18096083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study.
    Simcock M; Blasko M; Karrer U; Bertisch B; Pless M; Blumer L; Vora S; Robinson JO; Bernasconi E; Terziroli B; Moirandat-Rytz S; Furrer H; Hirschel B; Vernazza P; Sendi P; Rickenbach M; Bucher HC; Battegay M; Koller MT;
    Antivir Ther; 2007; 12(6):931-9. PubMed ID: 17926647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AIDS and non-Hodgkin's lymphoma. Experience at an oncological center in Mexico.
    Cornejo-Juárez P; Volkow-Fernández P; Avilés-Salas A; Calderón-Flores E
    Rev Invest Clin; 2008; 60(5):375-81. PubMed ID: 19227434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.